Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality

Philip N Sambrook, Jiang S Chen, Judy M Simpson and Lyn M March
Med J Aust 2010; 193 (3): 154-156.
  • Philip N Sambrook1
  • Jiang S Chen2
  • Judy M Simpson3
  • Lyn M March1

  • 1 Royal North Shore Hospital, Sydney, NSW.
  • 2 Institute of Bone and Joint Research, University of Sydney, Sydney, NSW.
  • 3 Sydney School of Public Health, University of Sydney, Sydney, NSW.


Competing interests:

Philip Sambrook serves on the medical advisory boards of and has received speaker fees from Amgen, Merck Sharp & Dohme, Novartis, Sanofi-Aventis and Servier.

  • 1. Einarson A, Schachtschneider AK, Halil R, et al. SSRI’s and other antidepressant use during pregnancy and potential neonatal adverse effects: impact of a public health advisory and subsequent reports in the news media. BMC Pregnancy Childbirth 2005; 5: 11.
  • 2. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
  • 3. McIntosh J, Blalock SJ. Effects of media coverage of Women’s Health Initiative study on attitudes and behavior of women receiving hormone replacement therapy. Am J Health Syst Pharm 2005; 62: 69-74.
  • 4. Yngve A, Hambraeus L, Lissner L, et al. The Women’s Health Initiative. What is on trial: nutrition and chronic disease? Or misinterpreted science, media havoc and the sound of silence from peers? Public Health Nutr 2006; 9: 269-272.
  • 5. Sambrook P. President’s report. Aust N Z Bone Miner Soc Newsletter 2008; Issue 8: 1. (accessed Sep 2008).
  • 6. Garvan Institute. Fracture risk calculator. (accessed Sep 2008, link updated Jul 2010).
  • 7. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; (1): CD001155.
  • 8. Wells GA, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; (1): CD004523.
  • 9. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822.
  • 10. Center J, Nguyen T, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353: 878-882.
  • 11. Fisher AA, O’Brien ED, Davis MW. Trends in hip fracture epidemiology in Australia: possible impact of bisphosphonates and hormone replacement therapy. Bone 2009; 45: 246-253.
  • 12. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22: 1479-1491.
  • 13. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65: 415-423.
  • 14. Sambrook PN, Olver I, Goss A. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician 2006; 35: 801-803.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.